ABSTRACT Lidocaine is a commonly used antiarrhythmic drug that causes use-dependent blockade of sodium channels in vitro and reduces conduction velocity in vitro and in vivo. According to the modulated receptor hypothesis of antiarrhythmic drug action, lidocaine has a low affinity for rested sodium channels but a high affinity for open and inactivated channels. In the present experiments, we characterized use-dependent conduction slowing and recovery from slowing by lidocaine in anesthetized dogs. The His-to-ventricular conduction interval was used as the indicator of conduction velocity. We found that prolongation of conduction time was greater as the stimulation frequency was increased. Moreover, on abruptly changing the stimulation frequency, a new steady-state conduction time was approached in two to three depolarizations. On discontinuation of stimulation, the conduction time of progressively less premature extrastimuli shortened exponentially with a terminal phase time constant of 152 115 msec. These effects by lidocaine were enhanced during acidosis and enhancement was reversed by correction of the acidosis. It is concluded that the effects in vivo of lidocaine on conduction under several conditions of rate, rhythm, and pH are similar to its effects on the maximum upstroke velocity of the action potential in vitro. Although these experiments were not designed to validate the modulated receptor hypothesis, it appears that the modulated receptor hypothesis can predict the effects of lidocaine on conduction in vivo. Circulation 74, No. 1, 205-214, 1986. LIDOCAINE blocks sodium channels in a voltageand time-dependent fashion.' These effects of lidocaine on the sodium current2 and the maximum upstroke velocity3' 4 of the cardiac action potential can be accounted for by the modulated receptor hypothesis.5 6 Briefly, when sodium channels are in the rested state, they have a low affinity for lidocaine, but when they are opened or inactivated by depolarization their affinity for lidocaine increases by several orders of magnitude.2 S As a result, during each action potential, the fraction of channels blocked by lidocaine increases, whereas during each diastole the fraction blocked de- 
LIDOCAINE blocks sodium channels in a voltageand time-dependent fashion.' These effects of lidocaine on the sodium current2 and the maximum upstroke velocity3' 4 of the cardiac action potential can be accounted for by the modulated receptor hypothesis.5 6 Briefly, when sodium channels are in the rested state, they have a low affinity for lidocaine, but when they are opened or inactivated by depolarization their affinity for lidocaine increases by several orders of magnitude.2 S As a result, during each action potential, the fraction of channels blocked by lidocaine increases, whereas during each diastole the fraction blocked de-creases. Thus the more closely the action potentials are coupled, the more time is available for block development and the less time for recovery from block. This accounts for frequency-or use-dependent effects on sodium-channel block and action potential upstroke velocity by lidocaine. Use-dependent behavior is also compatible with an alternative model, in which affinity for open and inactivated channels is constant, but drug access to the channel varies with changes in gate configuration during the action potential.6 The modulated receptor predictions have been extensively tested in vitro but not in vivo.7 Both sodium current and maximal upstroke velocity of action potential Vmax have been decreased by lidocaine in studies in vitro. Since maximum upstroke velocity is a major determinant of conduction velocity, 8.9 we predicted that lidocaine should produce use-dependent slowing of conduction in vivo. Conduction velocity is also an important variable in the pathophysiology of arrhythmia and in correction of arrhythmia by drugs.
By applying the modulated receptor hypothesis to sodium channel-dependent conduction, we predicted that (1) the slowing of conduction by lidocaine will increase as the cycle length is reduced, (2) Serum potassium and sodium concentrations were determined with an ion-selective electrode (Beckman-Astra); evaluations were performed in the Clinical Laboratories at the University of California, San Francisco. Serum lidocaine concentrations were determined by an immunoassay method (EMIT; Bioscience Laboratories, Oakland, CA). Arterial blood gases were measured in freshly sampled blood with a blood gas analyzer (Radiometer-Copenhagen).
Pacing protocols. These studies were designed to determine the influence of pacing rate on His-Purkinje conduction under control conditions and in the presence of lidocaine at normal pH, lidocaine during acidosis, and lidocaine after reversal of acidosis. We examined the onset, magnitude, and duration of use-dependent effects on conduction. The onset of use-dependent change was monitored during rapid His bundle pacing. The magnitude of steady-state conduction change was monitored by examining the His-ventricular (HV) interval during rapid atrial pacing. The duration of use-dependent change was determined by monitoring recovery from HV prolongation after rapid atrial pacing.
Onset of conduction slowing. Direct His bundle pacing was required to examine the onset of rate-related conduction change. Attempts to observe onset during rapid atrial pacing were complicated by refractoriness (accommodation) within the atrioventricular (AV) node. To avoid this limitation, we paced the His bundle directly with electrodes at the aortic root (sinus of Valsalva). To be sure that the His bundle was paced selectively, we required that the following criteria be met'0: (1) QRS and T wave morphology had to be similar to that during sinus rhythm and identical to that during atrial pacing at comparable rates, (2) stimulus-to-ventricular depolarization (SV) interval had to be within 5 msec of the HV interval recorded during atrial pacing, and (3) AV dissociation or retrograde ventriculoatrial conduction had to be present.
To monitor onset, the His bundle was paced rapidly at a cycle length of 200 msec. Five trains of 10 complexes were developed for each dog. The interval between the pacing stimulus and the subsequent ventricular depolarization (SV) was determined for each complex in the sequence 1 through 10 for all five trains. Next, mean SV value for the first depolarization of the five trains was calculated for each dog. Similarly, mean SV values for each numbered depolarization (1 through 10) were calculated for the five trains. A reference SV interval was obtained before drug, by pacing at a rate 10 per minute faster than the sinus rate. The change in mean SV interval or delta SV was expressed as a percentage of the reference SV value for each dog (see Data evaluation). Delta SV values for the first through the tenth stimulations at a cycle length of 200 msec were compared under the following conditions: control, lidocaine, lidocaine in acidosis, and lidocaine after reversal of acidosis.
Steady-state HV interval change. The magnitude of steadystate change in the HV interval was examined during atrial pacing. In preliminary experiments, we found that on abruptly changing the frequency of stimulation, AV node accommodation and stable His-to-His intervals developed within three to seven depolarizations. We also verified that administration of atropine did not measurably influence the HV interval in anesthetized dogs during sinus rhythm or rapid atrial pacing. Therefore measurements were taken after 10 depolarizations. Atropine (0.5 to 1.0 mg bolus) was given before pacing to facilitate accommodation within the AV node and to encourage 1: 1 AV conduction at rapid rates. 1 1 If AV conduction did not stabilize or AV Wenckebach periodicity was observed, the data were discarded. All atrial stimuli were 2 msec in duration and were applied at two to three times diastolic threshold.
The right atrium was paced for 10 depolarizations at each of the following cycle lengths (msec): 500, 400, 350, 300, 250, 230, 210, 200, and in 10 msec decrements thereafter until 1:1 AV conduction was no longer achieved. A 3 sec pause (sufficiently long to allow return to steady state; see Results) separated each train of 10 depolarizations. To evaluate rate-dependent effects of lidocaine, we measured the HV conduction time of the tenth depolarization of a train. The HV interval was measured from the first high-frequency component of the His spike to the first evidence of ventricular depolarization seen in surface or intracardiac recordings. To measure QRS duration, vertical lines were drawn at the first and last evidence of QRS inscription in three electrocardiographic surface leads I, III, and V1.
The interval between these lines was recorded as the QRS duration. All measurements for a given dog were obtained by the same investigator.
Recoveryfrom conduction slowing. Recovery was monitored by sampling the HV interval at progressively earlier points in CIRCULATION 206 diastole, after rapid pacing had created steady-state HV prolongation. To examine recovery, the right atrium was driven rapidly at a cycle length of 200 msec for 10 depolarizations (S1), after which a test stimulus (S2) was introduced, followed by a 3 sec pause. In successive pacing trains, the SI-S2 interval was reduced by 10 msec, starting from the longest possible SI-S2 (determined by the sinus escape complex) to the shortest possible SI-S2 (effective refractory period for AV conduction). For each programmed train, the HV interval of the tenth (HI) and test (H2) depolarizations were measured. Use of the H1-H2 coupling interval for reference avoided accommodation changes within the AV node. In early experiments, sinus tachycardia prevented sampling of recovery points in late diastole. To delay sinus recovery after pacing, we stimulated the distal ends of the cut right vagus nerve using a Grass SR-5 stimulator in five dogs. Duration of the vagal stimulus was fixed at 10 msec while voltage and frequency were varied to achieve up to 1.5 sec asystole immediately after the conditioning train. The presence or absence of vagal nerve stimulation did not affect the HV times of short coupling intervals.
Drug infusion. After control measurements were made, we infused 10 mg/kg lidocaine over 10 min. This was followed by a constant infusion of lidocaine at one of two rates. The infusion rate was set at 0.15 mg/kg/min to maintain serum lidocaine concentration in the 6 to 10 ,ug/ml range, or at 0.3 mg/kg/min to maintain serum lidocaine concentration at 10 to 12 ,gtg/ml. After 15 min for lidocaine distribution, the measurements were repeated, followed by a determination of serum potassium and serum lidocaine concentrations, P2, Pco2, and pH.
We then induced acidosis by infusing HCI solution into the left femoral vein at 2 meq/min. Arterial blood pH was monitored every 10 to 15 min. When blood pH reached the 7.0 to 7.2 range, the acid infusion was slowed to less than 0.5 meq/min. The pH remained unchanged during the period of acidosis at 7.19 ± 0.04 and 7.19 + 0.06pH units (p = NS), respectively, before and after test pacing.
Acidosis was reversed by infusing NaHCO3 in an amount equimolar to the HCI used to produce acidosis (50 to 100 meq). Small additional aliquots were then administered, if necessary, until a pH between 7.40 to 7.50 was reached. After reversal of acidosis, the measurements were repeated. After infusion of NaHCO3, the pH tended to drift slightly downward from 7.46 ± 0.07 to 7. 
Results
An example of drug-induced use-dependent change in His-Purkinje conduction and QRS duration is displayed in figure 1 . Under drug-free conditions, the HV interval did not significantly change when the spontaneous sinus cycle length of 410 msec was replaced by a paced cycle length of 210 msec ( figure 1, A) .
In the presence of lidocaine (10 ,g/ml), the HV interval and QRS duration remained unchanged at sinus or paced cycle lengths greater than 300 msec. However, as the cycle length was reduced below 300 msec, the HV and QRS intervals lengthened. At a cycle length of 210 msec, the HV interval increased by 6 msec (20%) and the QRS increased by 11 msec or 19% (figure 1). Similar use-dependent lengthening of the HV and QRS intervals was observed in all experiments in the presence of lidocaine. Since HV intervals are better delineated than QRS duration, we shall report changes in HV interval only. It should be emphasized, however, that the observed changes in HV interval were mirrored by changes in QRS duration. Furthermore, the QRS vector never changed abruptly, so changes in conduction interval probably reflect true changes in conduction velocity rather than gross changes in conduction pathway within the His-Purkinje system. At cycle lengths for which both HV and SV intervals were available, the lidocaine effects were comparable ( figure 3, B) . Like the HV interval, the SV interval was unchanged by shortening cycle length under control conditions but increased as cycle length was reduced in the presence of lidocaine. In bypassing the AV node, the His-Purkinje system could be activated at cycle lengths of 180 msec, at which lidocaine increased the SV interval by 39%.
Recovery from use-dependent HV prolongation by lido- caine. To monitor recovery, a conditioning train of 10
Vol. 74, No. 1, July 1986 rapid depolarizations was followed by a test stimulus that scanned the subsequent diastolic interval. Delta HV was then determined for each premature interval (HC-H2). During control atrial pacing, the H2-V2 interval of an S2-induced (test) depolarization did not change as the H-H2 interval was shortened from 1000 to 180 msec (figure 4). In the presence of lidocaine, the H2-V2 interval increased in an exponential fashion as HH2 was shortened, and this increase in H2-V2 was significant (p < .05) for all H1-H2 intervals 300 msec and shorter ( figure 4) .
In five dogs, right vagal nerve stimulation was used to increase the maximum diastolic time before sinus 60r- resting heart rates; only during tachycardia (cycle NTROL length less than 250 msec) does lidocaine slow conduc-DOCAINE + H tion. Thus rate-dependent actions by lidocaine on con-MOCAINE + HCO3 duction in vivo are very similar to its actions on Vma, in vitro. 3 15, 16 We measured use-dependent changes in conduction |* *T over a relatively fixed anatomic pathway, the HisPurkinje system. It should be stressed that lidocaine j T also prolonged QRS duration at rapid rates without significant changes in QRS vector. Thus it is unlikely that the measured effects of lidocaine on HV interval 2). Thus depression of conduction by lidocaine is almost fully developed by the second beat of a tachycardia. This contrasts with the action of slower drugs vas prolonged like quinidine or flecainide, with which the blockade r24% (n = 7) develops over 10 or more beats. These slower drugs 1 Slower time constants have been reported for recovery of the sodium current in vitro, but these studies were conducted at lower temperatures at which recovery proceeds more slowly. 2,13 In vivo, recovery of conduction also proceeded quickly after lidocaine (figure 4). Although recovery from conduction slowing also proceeded exponentially, analytic models and actual measurements suggest a quadratic relationship between upstroke velocity and conduction.8 '9 In view of this quadratic relationship, recovery kinetics for upstroke velocity and conduction may not be expected to be quantitatively identical.
Elfects of acidosis. In vitro, the recovery rate of Vmax .24 and the sodium current2 from lidocaine block are markedly slowed by acidosis. Our results show that recovery of conduction in the His-Purkinje system in vivo is similarly slowed by acidosis. Thus the effect of lidocaine on conduction after each rapid depolarization will persist longer in acidotic tissue than in tissue at normal pH, and the magnitude of steady-state effects will be greater. Yet, complete recovery from lidocaine effect would be expected during acidosis given a sufficiently long diastolic interval. With a T (slow) of 686 msec, use-dependent prolongation of the HV interval will decline to less than 1% of peak change after 3 sec of diastolic quiescence.25
The mechanism by which acidosis slowed recovery of conduction after lidocaine cannot be explained on the basis of these experiments alone. However, the observations are consistent with a previously postulated change in the fraction of charged lidocaine molecules. Acidosis increases the cationic form of lidocaine relative to the neutral form, and the charged form of the drug dissociates from (unblocks) the repolarized channel more slowly.4' 1 26 Our observation is compatible with slowed dissociation or slowed egress by lidocaine from the sodium channel in acidosis. Whether increased block development during each action potential was also important cannot be determined from the present experimental results.
Several alternative factors could contribute to the increased lidocaine effect. However, these are not supported by results reported in the literature, which include the following: (1) Extracellular potassium increases during acidosis.2`As shown by Chen et of His-Purkinje depolarization were similarly small during acidosis, increased lidocaine exposure to inactivated receptors would not be expected and could not account for the increased lidocaine effect on the HV interval during acidosis. Recovery from conduction slowing proceeded exponentially. In attempting to characterize the pattern of this exponential process, we found the data were better fit by double-and triple-exponential plots than by single exponentials. This probably reflects the multiple factors that have different magnitudes of influence on the HV interval as an expression of recovery from ratedependent conduction slowing by lidocaine. These factors might include the quadratic relationship between conduction velocity and Vmax,Q 9 dynamic drug ionization, and drug-channel dissociation after repolarization.7 Single,4 double,22 25 and triple3' exponentials have been used to characterize recovery from use-dependent block by lidocaine in vitro. Although we do not have a definitive indication of the exponential equations that optimally characterize recovery in vivo, modulated receptor equations do not consider conduction explicitly and can be used only indirectly to predict the pattern of recovery for a drug given in vivo.
Clinical relevance. Our observations regarding the effects of lidocaine on cardiac conduction have important clinical implications. Lidocaine should be most effective in suppressing rapid clinical arrhythmias that are sensitive to drug-induced conduction slowing or conduction block,32 33 especially when occurring in acidotic environments. Ischemic myocardial infarction is accompanied by profound regional myocardial extracellular acidosis (pH ' 7.0), along with hyperkalemia (K' 12 to 14 meq/liter) and hypoxia.3137 We observed that acidosis, even without hyperkalemia, significantly augments lidocaine's effect in vivo at very rapid rates, slowing conduction by more than 50% (figure 5). Ischemia is frequently associated with arrhythmias.11 Acidosis will augment and prolong lidocaine effects on conduction, and any dose of lidocaine will have more effect on conduction in ischemic tissue than in nonischemic tissue. 39 42 Clinically, lidocaine has been more effective in controlling ventricular fibrillation than ventricular tachycardia in patients with acute myocardial infarction. 43 In contrast, reentrant ventricular arrhythmia in nonischemic myocardium appears to be less responsive to lidocaine in experimental'6 and clinical"4 settings.
In summary, use-dependent slowing of conduction and recovery from use-dependent block can be measured in vivo. The kinetics of these effects are comparable to those previously measured in vitro. Moreover, use-dependent slowing of conduction is accentuated by tachycardia and acidosis. These effects can be accounted for by the modulated receptor hypothesis. Thus the use-dependent effects of lidocaine on conduction in vivo compare well with lidocaine effects on Vmax and the sodium current.
